PMID- 37859622
OWN - NLM
STAT- MEDLINE
DCOM- 20231113
LR  - 20231113
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Print)
IS  - 1021-335X (Linking)
VI  - 50
IP  - 6
DP  - 2023 Dec
TI  - Licochalcone A induces cell cycle arrest and apoptosis via suppressing MAPK 
      signaling pathway and the expression of FBXO5 in lung squamous cell cancer.
LID - 214 [pii]
LID - 10.3892/or.2023.8651 [doi]
AB  - Lung squamous cell carcinoma (LSCC) is a highly heterogeneous malignancy with 
      high mortality and few therapeutic options. Licochalcone A (LCA, PubChem ID: 
      5318998) is a chalcone extracted from licorice and possesses anticancer and 
      anti‑inflammatory activities. The present study aimed to elucidate the anticancer 
      effect of LCA on LSCC and explore the conceivable molecular mechanism. MTT assay 
      revealed that LCA significantly inhibited the proliferation of LSCC cells with 
      less cytotoxicity towards human bronchial epithelial cells. 
      5‑ethynyl‑2'‑deoxyuridine (EdU) assay demonstrated that LCA could reduce the 
      proliferation rate of LSCC cells. The flow cytometric assays indicated that LCA 
      increased the cell number of the G1 phase and induced the apoptosis of LSCC 
      cells. LCA downregulated the protein expression of cyclin D1, cyclin E, CDK2 and 
      CDK4. Meanwhile, LCA increased the expression level of Bax, cleaved 
      poly(ADP‑ribose)polymerase‑1 (PARP1) and caspase 3, as well as downregulated the 
      level of Bcl‑2. Proteomics assay demonstrated that LCA exerted its antitumor 
      effects via inhibiting mitogen‑activated protein kinase (MAPK) signaling pathways 
      and the expression of F‑box protein 5 (FBXO5). Western blot analysis showed that 
      LCA decreased the expression of p‑ERK1/2, p‑p38MAPK and FBXO5. In the xenograft 
      tumors of LSCC, LCA significantly inhibited the volumes and weight of tumors in 
      nude mice with little toxicity in vital organs. Therefore, the present study 
      demonstrated that LCA effectively inhibited cell proliferation and induced 
      apoptosis in vitro, and suppressed xenograft tumor growth in vivo. LCA may serve 
      as a future therapeutic candidate of LSCC.
FAU - Fan, Xiaoli
AU  - Fan X
AD  - Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, 
      Hunan 410013, P.R. China.
FAU - Guan, Guoqiang
AU  - Guan G
AD  - College of Pharmacy, Guilin Medical University, Guilin, Guangxi 541199, P.R. 
      China.
FAU - Wang, Juan
AU  - Wang J
AD  - College of Pharmacy, Guilin Medical University, Guilin, Guangxi 541199, P.R. 
      China.
FAU - Jin, Meihua
AU  - Jin M
AD  - Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, P.R. 
      China.
FAU - Wang, Liming
AU  - Wang L
AD  - Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, P.R. 
      China.
FAU - Duan, Xiaoqun
AU  - Duan X
AD  - Industrial Technology Research Institute of Pharmacy, Guilin Medical University, 
      Guilin, Guangxi 541199, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20231020
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Chalcones)
RN  - 0 (F-Box Proteins)
RN  - 0 (FBXO5 protein, human)
RN  - JTV5467968 (licochalcone A)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Mice
MH  - Apoptosis
MH  - *Carcinoma, Squamous Cell/drug therapy/genetics/metabolism
MH  - Cell Cycle Checkpoints/drug effects/genetics
MH  - Cell Cycle Proteins/metabolism
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - *Chalcones/pharmacology/therapeutic use
MH  - *F-Box Proteins/metabolism
MH  - Lung/pathology
MH  - Mice, Nude
MH  - Mitogen-Activated Protein Kinases/metabolism
MH  - Signal Transduction
MH  - *Lung Neoplasms/drug therapy/genetics/metabolism
PMC - PMC10620845
OTO - NOTNLM
OT  - F‑box protein 5
OT  - apoptosis
OT  - licochalcone A
OT  - lung squamous cell carcinoma
OT  - proteomics
COIS- The authors declare that they have no competing interests.
EDAT- 2023/10/20 06:42
MHDA- 2023/10/23 01:18
PMCR- 2023/10/20
CRDT- 2023/10/20 04:15
PHST- 2023/06/13 00:00 [received]
PHST- 2023/10/02 00:00 [accepted]
PHST- 2023/10/23 01:18 [medline]
PHST- 2023/10/20 06:42 [pubmed]
PHST- 2023/10/20 04:15 [entrez]
PHST- 2023/10/20 00:00 [pmc-release]
AID - 214 [pii]
AID - OR-50-6-08651 [pii]
AID - 10.3892/or.2023.8651 [doi]
PST - ppublish
SO  - Oncol Rep. 2023 Dec;50(6):214. doi: 10.3892/or.2023.8651. Epub 2023 Oct 20.